Dec. 4, 2024 — Researchers have uncovered a serious side effect of using the CRISPR-Cas gene scissors. A molecule designed to make the process more efficient destroys parts of the ...

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $41.07, representing a +0.32% change from its previous close. These five geonomics and synthetic biology stocks are likely to ...

There are only a handful of kids in the world with Lucy's disorder, which is called PGAP-3 CDG. There's no way to treat it.

The global prime editing and CRISPR market size was US$ 3,194.2 million in 2021. The global prime editing and CRISPR market is forecast to grow to US$ 17,618.4 million by 2030 by registering a ...

Thanks to CRISPR, medical specialists will soon have unprecedented control over how they treat and prevent some of the most challenging genetic disorders and diseases. CRISPR (Clustered Regularly ...

CRISPR Therapeutics had its first FDA-approved product in December 2023, a treatment for sickle cell disease called Casgevy. It’s also developing treatments for cancer and cardiovascular disease ...

Using CRISPR-Cas13 to edit RNA and avoid off-target activity, the researchers systematically profiled nearly 6,200 gene pairs ...

On Nov. 21, shares of CRISPR Therapeutics (NASDAQ: CRSP) were down 47% from a peak they reached in March. This might be a little surprising to folks who have been following this developer of gene ...